GlassScriptPhysician profile
Judith Ogan Son
NPI 1518012632
$3,848.06
in general payments reported to CMS, 2019-2025
34 companies · $979 in 2025
The $979 reported for 2025 was more than what 84% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $197 · 2020: $189 · 2021: $770 · 2022: $537 · 2023: $601 · 2024: $575 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $453.12 | 2021-2025 | Qulipta, Ubrelvy |
| Janssen Pharmaceuticals, INC | $381.93 | 2019-2023 | Spravato |
| Pfizer INC. | $307.49 | 2019-2025 | |
| Novo Nordisk INC | $295.49 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $265.50 | 2023-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Lilly USA, LLC | $225.67 | 2021-2025 | Zepbound, Mounjaro, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $212.58 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $172.38 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $161.88 | 2019-2023 | Farxiga |
| Bayer Healthcare Pharmaceuticals INC. | $137.55 | 2022-2025 | |
| Kowa Pharmaceuticals America, INC. | $123.21 | 2021-2025 | Zoryve |
| Antares Pharma, INC. | $119.08 | 2025 | Xyosted |
| Amgen INC. | $102.67 | 2019-2024 | Evenity, Prolia |
| Electromed, INC. | $88.52 | 2022-2024 | Smartvest |
| Exact Sciences Corporation | $87.19 | 2024-2025 | Cologuard Collection Kit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $80.63 | 2020-2023 | Yupelri |
| Dexcom, INC. | $63.40 | 2020-2022 | |
| Xeris Pharmaceuticals, INC. | $51.37 | 2024-2025 | Gvoke Hypopen |
| Glaxosmithkline, LLC. | $50.26 | 2025 | Shingrix, Arexvy |
| Biohaven Pharmaceuticals, INC. | $47.24 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $46.34 | 2019 | |
| Bausch Health US, LLC | $45.57 | 2024-2025 | Aplenzin |
| Biohaven Pharmaceutical Holding Company LTD. | $40.47 | 2022 | |
| Nevro Corp. | $36.07 | 2021 | |
| Arbor Pharmaceuticals, INC. | $35.73 | 2020 | |
| Astellas Pharma US INC | $35.39 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $35.34 | 2020-2021 | |
| Hologic Sales and Service, LLC | $34.41 | 2022-2023 | Aptima, Thinprep 2000 Processor |
| Viatris Specialty LLC | $23.43 | 2025 | Yupelri |
| Medtronic, INC. | $22.82 | 2024 | Intellis Adaptivestim |
| Radius Health, INC. | $21.71 | 2020 | |
| Linus Health, INC. | $17.36 | 2024 | Core Cognitive Evaluation |
| Echosens North America, INC. | $13.24 | 2024 | Fibroscan |
| Allergan, INC. | $13.02 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Judith Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.